Research programme: immuno-oncology therapeutics - Palvella Therapeutics/Seagen
Alternative Names: Research programme: antibody-Anticalin fusion proteins - Palvella Therapeutics/SeagenLatest Information Update: 17 Dec 2024
At a glance
- Originator Pieris Pharmaceuticals; Seattle Genetics
- Developer Palvella Therapeutics; Seagen
- Class Antibodies; Antineoplastics; Immunotherapies; Lipocalins; Recombinant fusion proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 13 Dec 2024 Pieris Pharmaceuticals has merged with Palvella Therapeutics to form Palvella Therapeutics
- 28 Sep 2024 No recent reports of development identified for preclinical development in Haematological-malignancies in USA
- 28 Sep 2024 No recent reports of development identified for preclinical development in Solid-tumours in USA